about
Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix.A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma: II. Its impact on clinical response and subsequent surgery.A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case reportClear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.Biology and treatment of cervical adenocarcinomaA case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic reviewA retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky massChemoradiotherapy with irinotecan (CPT-11) for adenoid cystic carcinoma of Bartholin's gland: A case report and review of the literature.The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathyPhase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky massSignificance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).Establishment and characterization of novel human uterine leiomyosarcoma cell lines.Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma.Implications of adrenomedullin expression in the invasion of squamous cell carcinoma of the uterine cervix.Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case reportSurgical management of non-invasive uterine clear cell carcinoma.Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer.Triple simultaneous primary invasive gynecological malignancies: a case report.Clinical utility of CA-125 in the management of uterine carcinosarcoma[Usefulness of magnetic resonance imaging (MRI) in the detection of the lesions of gestational trophoblastic disease--comparison with computed tomography and digital subtraction angiography][A case of young woman with giant ovarian tumor as the manifestation of leukemic recurrence]Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma: I. Analysis for pharmacokinetics, tumor response, and toxicity of platinumEstimation of stem cell fractions in peripheral blood stem cell harvest by using an SE-9000 hematology analyzerFactors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervixAdjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovaryThe impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study[Malignant germ cell tumor--outline]Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: a Kansai Clinical Oncology Group study (KCOG9812)[Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer][Gynecologic cancer]
P50
Q33401294-0072B3F6-F4A2-43B9-A008-71EE6120E584Q33404946-AB2B2255-6739-40F1-B6F4-4FE150D532D7Q33406474-25BFA1E3-7D00-4143-924E-E61023E56B07Q33408632-6CEBA4DE-D9E7-4AAA-80D3-5337A132D9E9Q34280537-2208C94B-D14D-4EE1-8BB1-8EBA12A5E23FQ35965914-12BF35C5-47E9-4792-A96D-39939D19021BQ36461591-B771D8A4-814E-4E99-971B-8A82CE308F2FQ36897270-3EA00C55-157F-452E-9335-025318271818Q37169282-11A97EF5-2F3E-4A8B-B82B-7ACEA5FEE247Q37265725-F8739E9C-C1A8-477E-88D7-E6EAA10C8F95Q37390062-19A01B83-BE35-4AEB-8F96-F9868AD25D16Q37417070-2763D1DB-146D-41D0-A6DA-FBEEDAE9FC4AQ37443118-ACAA7A03-21FC-4824-9309-6F689F435C32Q38381194-BD3A11E8-D051-41DF-A3D5-1E42661E2B8FQ38705385-F0301013-0689-4617-9627-910FF4D6C28CQ39698135-786AB301-CDA1-4FF9-8E7C-698266027D95Q40434636-A1504759-3BA3-446E-AA55-7AC239E8CB34Q40752669-C6FB6AC1-EB09-4FF5-A1D8-8D4D2F2B5864Q41912876-A20B3388-841A-45A9-A4D0-2749B5AD9C79Q42345755-BFAE501E-2A31-46B3-AF5D-45D08264C3FFQ44654133-680F8B8E-E510-47C6-AA1F-4DA21296FA01Q48071958-0E071D8D-353E-4136-B5DF-6D76655A64B5Q53101122-DAB6D719-F262-41E1-8C2C-D62387F2BEF6Q57209989-6422D041-8A57-4582-8B24-D8BA841BC2E9Q67842390-892B80AD-6CB7-417D-80C9-7DE8A47CD8B3Q68897810-05BFD0DF-7564-44B0-B85E-D0A03192B832Q74015423-553AE630-E1D3-4530-B7D7-1F897901D6B5Q74163841-158FEB56-8A2B-4E27-8A55-827FEE55AC73Q77564927-966D8E30-7095-4952-B92B-A723D70F1DFCQ79335017-62C750FF-9261-44B2-9315-5BC05090FC75Q82241030-FF2D2524-99BC-4597-8C23-95201A336154Q85457072-DFBEF0E8-5F1E-4B0D-AD6A-87443B774C68Q87440391-B5C93515-8AAC-4707-A71F-56471236511AQ95440156-763A8EB7-716C-4280-A12A-3B4815359B40Q95584459-0A5AD449-032A-449E-A16F-2FAED82A6527
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-8868-6462
@en
name
Satoshi Takeuchi
@ast
Satoshi Takeuchi
@en
Satoshi Takeuchi
@es
Satoshi Takeuchi
@nl
type
label
Satoshi Takeuchi
@ast
Satoshi Takeuchi
@en
Satoshi Takeuchi
@es
Satoshi Takeuchi
@nl
prefLabel
Satoshi Takeuchi
@ast
Satoshi Takeuchi
@en
Satoshi Takeuchi
@es
Satoshi Takeuchi
@nl
P106
P31
P496
0000-0001-8868-6462